静脉血栓栓塞症的原发性及继发性危险因素分析
Analysis of the Primary and Secondary Risk Factors of Venous Thromboembolism
DOI: 10.12677/ACM.2022.125707, PDF,    科研立项经费支持
作者: 许风雷:新疆克拉玛依市中心医院神经内科,新疆 克拉玛依;胡 军, 孜莱克, 周 琴, 菅辉玲, 张益枝, 高丽霞*:新疆克拉玛依市中心医院血液肿瘤科,新疆 克拉玛依
关键词: 静脉血栓栓塞症蛋白C蛋白S抗凝血酶III继发性危险因素Venous Thromboembolism Protein C Protein S Antithrombin III Secondary Risk Factors
摘要: 目的:通过分析108例静脉血栓栓塞症(VTE)患者的临床资料,检查患者蛋白C (PC)、蛋白S (PS)、抗凝血酶III (ATIII)活性水平,探讨原发性和继发性危险因素与静脉血栓栓塞症的关系,为VTE的及早预防提供理论依据。方法:收集克拉玛依市中心医院108例VTE病例组(2014年1月至2019年1月收治的VTE)及52例对照组患者的临床资料,检测PC、PS、ATIII活性等指标,分析抗凝蛋白缺陷与VTE的关系,及患者年龄、性别、临床特征及继发性危险因素。结果:VTE患者的PC、PS、ATIII活性结果与对照组比较明显降低,差异有统计学意义(P < 0.05)。以PS缺陷所占比例最多(18.5%),其次是PC缺陷(13.7%)和ATIII缺陷10.5%),差异具有统计学意义(χ2 = 25.46, P < 0.05)。复发组与初发组比较抗凝蛋白缺陷发病率差异具有统计学意义(χ2 = 5.733, P < 0.05),继发性危险因素中前二位是外伤/手术(骨科手术最多)、恶性肿瘤(消化道肿瘤 > 肺癌 > 妇科肿瘤 > 泌尿系肿瘤 > 乳腺癌)。恶性肿瘤合并VTE患者的比例最高。结论:蛋白C (Protein C, PC)、蛋白S (Protein S, PS)和抗凝血酶III (Antithrombin III, ATIII)缺陷是促发VTE发生的重要原发性危险因素,以PS、PC缺陷为主,抗凝蛋白缺陷可能是血栓复发的重要危险因素。继发性危险因素以外伤/手术和恶性肿瘤为主。多种因素并存是引起VTE的重要原因。
Abstract: Objective: By analyzing the clinical data of 108 patients with VTE, the activity levels of protein C (PC), protein S (PS), antithrombin III (ATIII) were examined, and the relationship between the primary and secondary risk factors and VTE was discussed to provide theoretical basis for the early preven-tion of VTE. Method: The clinical data of 108 cases of VTE (VTE admitted from January 2014 to Janu-ary 2019) and clinical data of 52 patients in the control group were collected to detect the activity of PC, PS and ATIII, analyze the relationship between anticoagulant protein deficiency and VTE, and the age, gender, clinical characteristics and secondary risk factors of patients. Results: The activity of PC, PS and ATIII in VTE patients was significantly lower than that in the control group (P < 0.05). PS defects accounted for the most (18.5%). The difference was statistically significant (χ2 = 25.46, P < 0.05). The incidence rate of anticoagulant protein deficiency in relapse group was significantly different from that in the initial group (χ2 = 5.733, P < 0.05). The top two secondary risk factors were trauma/surgery (Department of orthopedics operation), malignant tumor. The proportion of patients with VTE is the highest. Conclusion: The defects of PS, PC and at ATIII are the important primary risk factors for VTE. The defect of anticoagulant protein may be the important risk factors for thrombosis recurrence. The main secondary risk factors were trauma/operation and malignant tumor. The coexistence of many factors is an important cause of VTE.
文章引用:许风雷, 胡军, 孜莱克, 周琴, 菅辉玲, 张益枝, 高丽霞. 静脉血栓栓塞症的原发性及继发性危险因素分析[J]. 临床医学进展, 2022, 12(5): 4877-4884. https://doi.org/10.12677/ACM.2022.125707

参考文献

[1] Huang, W., Goldberg, R.J., Anderson, F.A., et al. (2014) Secular Trends in Occurrence of Acute Venous Thromboem-bolism: The Worcester VTE Study (1985-2009). The American Journal of Medicine, 127, 829-839. [Google Scholar] [CrossRef] [PubMed]
[2] Basil, N., Ekstrm, M., Piitulainen, E., et al. (2021) Severe Al-pha-1-Antitrypsin Deficiency Increases the Risk of Venous Thromboembolism. Journal of Thrombosis and Haemosta-sis, 19, 1519-1525. [Google Scholar] [CrossRef] [PubMed]
[3] Fukaya, E., Flores, A.M., Lindholm, D., et al. (2018) Clinical and Genetic Determinants of Varicose Veins. Circulation, 138, 2869-2880. [Google Scholar] [CrossRef
[4] Griffin, J.H., Evatt, B., Zimmerman, T.S., et al. (1981) Deficiency of Protein C in Congenital Thrombotic Disease. Journal of Clinical Investigation, 68, 1370-1373. [Google Scholar] [CrossRef
[5] Fitzmaurice, D., Fletcher, K., Greenfield, S., et al. (2020) Prevention and Treatment of Venous Thromboembolism in Hospital and the Community: A Research Programme Including the ExACT RCT. Programme Grants for Applied Research, 8, 1-104. [Google Scholar] [CrossRef
[6] Ahmad, A., Sundquist, K., Palmer, K., et al. (2019) Risk Prediction of Recurrent Venous Thromboembolism: A Multiple Genetic Risk Model. Journal of Thrombosis and Thrombolysis, 47, 216-226. [Google Scholar] [CrossRef] [PubMed]
[7] Bucciarelli, P., Passamonti, S.M., Biguzzi, E., et al. (2012) Low Borderline Plasma Levels of Antithrombin, Protein C and Protein S Are Risk Factors for Venous Thromboembolism. Journal of Thrombosis and Haemostasis, 10, 1783-1791. [Google Scholar] [CrossRef] [PubMed]
[8] 中华医学会外科学会血管外科组. 深静脉血栓形成的诊断和治疗指南(第三版) [J]. 中华普通外科杂志, 2017, 32(9): 807-812.
[9] 邵翔, 司超增, 甄凯元, 等. 医院相关性静脉血栓栓塞症的临床特征及相关危险因素分析[J]. 中华血液学杂志, 2020, 100(20): 1539-1543.
[10] Fukaya, E., Flores, A.M., Lindholm, D., et al. (2019) Clinical and Genetic Determinants of Varicose Veins: Prospective, Community-Based Study of ≈500000 Individuals. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 7, 283-284. [Google Scholar] [CrossRef
[11] Enden, T., Haig, Y., Klow, N.E., et al. (2012) Long-Term Outcome after Additional Catheter-Directed Thrombolysis versus Standard Treatment for Acute Iliofemoral Deep Vein Thrombosis (the CaVenT Study): A Randomised Controlled Trial. The Lancet, 379, 31-38. [Google Scholar] [CrossRef
[12] Sciascia, S., Baldovino, S., Schreiber, K., et al. (2016) Thrombotic Risk Assessment in Antiphospholipid Syndrome: The Role of New Antibody Specificities and Thrombin Generation Assay. Clinical and Molecular Allergy, 14, 6. [Google Scholar] [CrossRef] [PubMed]
[13] 车焱. 我国妇产科静脉血栓栓塞症发生率研究现状[J]. 中国实用妇科与产科杂志, 2018, 34(7): 709-713.
[14] Bates, S.M., Jaeschke, R., Stevens, S.M., et al. (2012) Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest Journal, 141, 351-418. [Google Scholar] [CrossRef] [PubMed]
[15] Tinholt, M., Sandset, P.M., Iversen, N., et al. (2016) Polymorphisms of the Coagulation System and Risk of Cancer. Thrombosis Research, 140, 49-54. [Google Scholar] [CrossRef
[16] Souto, J.C., Almasy, L., Borrell, M., et al. (2000) Genetic Susceptibility to Thrombosis and Its Relationship to Physiological Risk Factors: The GAIT Study. The American Journal of Human Genetics, 67, 1452-1459. [Google Scholar] [CrossRef] [PubMed]
[17] Chung, D., Chen, J.M., Ling, M.H., et al. (2016) High-Density Lipoprotein Modulates Thrombosis by Preventing von Willebrand Factor Self-Association and Subsequent Platelet Adhesion. Blood, 127, 637-645. [Google Scholar] [CrossRef] [PubMed]
[18] Riva, N., Donadini, M.P. and Ageno, W. (2014) Epidemiology and Pathophysiology of Venous Thromboembolism: Similarities with Atherothrombosis and the Role of Inflammation. Thrombosis and Haemostasis, 13, 1176-1183.